Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO.

Br J Cancer · 2021 · PMC7782547 · PMID 33024268

Europe PMC DOI

hedged sentence

0.0830

closest p · 1.7× alpha

0.0830

boldest claim

The sentences

a positive trendP = 0.083so close (0.05 < p ≤ 0.1)

Among patients with an OIFI ≥ 4 months FOLFOXIRI ± bev reintroduction led to a positive trend towards better 2nd PFS when compared to doublets ± bev (median 2nd PFS: 7.2 versus 5.6 months, HR: 0.77 (95% CI: 0.58–1.04), P = 0.083), and to longer 2nd PFS compared to other treatments (median 2nd PFS: 7.2 versus 4.9 months, HR: 0.69 (95% CI: 0.50–0.95), P = 0.022) (Fig. 4a ).

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.